Immunogenicity and Safety of Pentaxim in South African Infants

Inclusion Criteria: * Aged \< 24 hours on the day of inclusion Exclusion Criteria: * At visit 01 (screening) * Illness at a stage that could interfere with trial conduct or completion. * Any vaccination preceding the trial participation (except Bacille Calmette-Guerin \[BCG\]) * Acute illness on the day of screening. At visit 01 and visit 02 (screening and first study vaccination). * Planned participation in another clinical trial during the present trial period * Blood or blood-derived products received since birth. * Mother known as seropositive to HIV or hepatitis B. * Known thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination * History of/current seizures at visit 02 (first study vaccination) * Participation in another clinical trial preceding the first trial vaccination * Congenital or acquired immunodeficiency; immunosuppressive therapy such as long-term systemic corticosteroid therapy. * Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances * Chronic illness at a stage that could interfere with trial conduct or completion. * Any vaccination preceding the first trial vaccination (except BCG) * History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b and hepatitis B infection (confirmed either clinically, serologically or microbiologically). * Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type b and hepatitis B infection with the trial vaccine or another vaccine. * Febrile illness (rectal temperature ≥ 38.0°C or axillary temperature ≥ 37.4°C) or acute illness on the day of first vaccination